Human endogenous retrovirus K envelope protein (HERV-K Env) (HERV-K Env)

Human endogenous retrovirus K (HERV-K) envelope protein is a protein encoded by the HERV-K (HML-2) family of endogenous retroviruses, which are remnants of ancient viral infections integrated into the human genome (Subramanian et al., 2011, Journal of Virology). While typically silenced in healthy adult tissues through epigenetic mechanisms, HERV-K Env is frequently reactivated and overexpressed in various malignancies, including breast cancer, melanoma, and germ cell tumors (Wang-Johanning et al., 2012, Journal of Clinical Investigation). It is also implicated in certain neurodegenerative conditions, most notably Amyotrophic Lateral Sclerosis (ALS), where its expression in motor neurons is linked to neurotoxicity (Li et al., 2015, Science Translational Medicine). In the context of cancer, the protein is thought to promote cell proliferation, migration, and immune evasion, potentially acting as a co-factor in tumor progression and metastasis. Because it is expressed on the cell surface of malignant cells but largely absent from normal cells, it is considered a highly specific tumor-associated antigen (TAA). Therapeutic approaches currently under investigation include monoclonal antibodies, therapeutic vaccines, and chimeric antigen receptor (CAR) T-cell therapies aimed at inducing targeted cell death (Krishnamurthy et al., 2015, Clinical Cancer Research). These therapies leverage the unique presence of the viral protein on the tumor surface to achieve high specificity and minimize off-target effects. Clinical trials are ongoing to evaluate the safety and efficacy of these HERV-K-targeted agents in patients with advanced solid tumors.

Other names

HERV-KERVKEnvKHK2Human endogenous retrovirus K10HML-2 envelope proteinHERV-K102

Targeting of tumor cells expressing HERV-K envelope protein via chimeric antigen receptor (CAR) T-cell therapy or monoclonal antibody-mediated cytotoxicity (ADCC/CDC).